A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection

BMC Urology

Volumn 12, Issue , 2012, Pages

  Van Neste, Leander ^a   Bigley, Joseph ^a   Toll, Adam ^b   Otto, Gaëtan ^a   Clark, James ^a   Delrée, Paul ^c   Van Criekinge, Wim ^a   Epstein, Jonathan I ^b  

^a MDxHealth   (Belgium)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Institut de Pathologie and Genetique   (Belgium)

Author keywords

APC; Diagnosis; Epigenetics; GSTP1; Methylation; MSP; Multiplex; Prostate cancer; RASSF1; Singleplex

Indexed keywords

APC PROTEIN; GLUTATHIONE TRANSFERASE P1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; COPY NUMBER VARIATION; EPIGENETICS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METHYLATION; MULTIPLEX POLYMERASE CHAIN REACTION; NEEDLE BIOPSY; OUTCOME ASSESSMENT; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION;

ADENOCARCINOMA; CASE-CONTROL STUDIES; COHORT STUDIES; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENES, APC; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84861802954     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-12-16     Document Type: Article

References (32)

1. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, Marberger M, J Urol 2000 163 4 1144 1148 discussion 1148-1149 10.1016/S0022-5347(05)67711-7 10737484
2. Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies. Troyer DA, Lucia MS, de Bruine AP, Mendez-Meza R, Baldewijns MM, Dunscomb N, Van Engeland M, McAskill T, Bierau K, Louwagie J, et al. Cancer Epidemiol Biomarkers Prev 2009 18 10 2717 2722 10.1158/1055-9965.EPI-09-0068 19755651
3. Analysis of repeated biopsy results within 1year after a noncancer diagnosis. O'Dowd GJ, Miller MC, Orozco R, Veltri RW, Urology 2000 55 4 553 559 10.1016/S0090-4295(00)00447-7 10736500 (Pubitemid 30157961)
4. Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Kronz JD, Allan CH, Shaikh AA, Epstein JI, Am J Surg Pathol 2001 25 8 1079 1085 10.1097/00000478-200108000-00014 11474294 (Pubitemid 32685907)
5. Mortality results from a randomized prostate-cancer screening trial. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, et al. N Engl J Med 2009 360 13 1310 1319 10.1056/NEJMoa0810696 19297565
6. Screening and prostate-cancer mortality in a randomized European study. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, et al. N Engl J Med 2009 360 13 1320 1328 10.1056/NEJMoa0810084 19297566
7. A retrospective and prospective overview of prostate-specific antigen. Ablin RJ, J Cancer Res Clin Oncol 1997 123 11-12 583 594 9620215 (Pubitemid 28035496)
8. The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience. Smith DS, Humphrey PA, Catalona WJ, Cancer 1997 80 9 1852 1856 10.1002/(SICI)1097-0142(19971101)80:9<1852::AID- CNCR25>3.0.CO;2-3 9351559 (Pubitemid 27475948)
9. Screening for prostate cancer: a review of the evidence for the u.s. preventive services task force. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, Gleitsmann K, Koenig HC, Lam C, Maltz A, et al. Ann Intern Med 2011 155 11 762 771 21984740
10. Gene silencing in cancer in association with promoter hypermethylation. Herman JG, Baylin SB, N Engl J Med 2003 349 21 2042 2054 10.1056/NEJMra023075 14627790 (Pubitemid 37448928)
11. Hypermethylation of the 5' region of the calcitonin gene is a property of human lymphoid and acute myeloid malignancies. Baylin SB, Fearon ER, Vogelstein B, de Bustros A, Sharkis SJ, Burke PJ, Staal SP, Nelkin BD, Blood 1987 70 2 412 417 3607279 (Pubitemid 17142924)
12. Methylation of the Hprt gene on the inactive X occurs after chromosome inactivation. Lock LF, Takagi N, Martin GR, Cell 1987 48 1 39 46 10.1016/0092-8674(87)90353-9 3791414
13. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. Schuebel KE, Chen W, Cope L, Glockner SC, Suzuki H, Yi JM, Chan TA, Van Neste L, Van Criekinge W, van den Bosch S, et al. PLoS Genet 2007 3 9 1709 1723 17892325 (Pubitemid 47510263)
14. Quantitative, spatial resolution of the epigenetic field effect in prostate cancer. Mehrotra J, Varde S, Wang H, Chiu H, Vargo J, Gray K, Nagle RB, Neri JR, Mazumder A, Prostate 2008 68 2 152 160 10.1002/pros.20675 18058812 (Pubitemid 351186227)
15. Extended field prostate biopsy enhances cancer detection. Babaian RJ, Urology 2000 55 4 453 456 10.1016/S0090-4295(00)00469-6 10736482 (Pubitemid 30157943)
16. Extended field prostate biopsies: too much of a good thing? Terris MK, Urology 2000 55 4 457 460 10.1016/S0090-4295(00)00450-7 10736483 (Pubitemid 30157944)
17. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. Partin AW, Brawer MK, Bartsch G, Horninger W, Taneja SS, Lepor H, Babaian R, Childs SJ, Stamey T, Fritsche HA, et al. J Urol 2003 170 5 1787 1791 10.1097/01.ju. 0000092695.55705.dd 14532777 (Pubitemid 37254929)
18. Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. Trock BJ, Brotzman MJ, Mangold LA, Bigley JW, Epstein JI, McLeod D, Klein EA, Jones JS, Wang S, McAskill T, et al. BJU Int 2011 10.1111/j.1464-410X.2011.10718.x
19. Promoter methylation in prostate cancer and its application for the early detection of prostate cancer using serum and urine samples. Ahmed H, Biomark Cancer 2010 2010 2 17 33 20657713
20. Assessing the accuracy of prediction algorithms for classification: an overview. Baldi P, Brunak S, Chauvin Y, Andersen CA, Nielsen H, Bioinformatics 2000 16 5 412 424 10.1093/bioinformatics/16.5.412 10871264 (Pubitemid 30487963)
21. Screening for prostate cancer: an update of the evidence for the U.S. preventive services task force. Harris R, Lohr KN, Ann Intern Med 2002 137 11 917 929 12458993 (Pubitemid 35416628)
22. A PSA threshold of 4.0 ng/mL for early detection of prostate cancer: the only rational approach for men 50 years old and older. Carter HB, Urology 2000 55 6 796 799 10.1016/S0090-4295(00)00517-3 10840079 (Pubitemid 30330773)
23. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, et al. JAMA 1998 279 19 1542 1547 10.1001/jama.279.19.1542 9605898 (Pubitemid 28233009)
24. Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. McGarvey KM, Van Neste L, Cope L, Ohm JE, Herman JG, Van Criekinge W, Schuebel KE, Baylin SB, Cancer Res 2008 68 14 5753 5759 10.1158/0008-5472.CAN-08-0700 18632628
25. Hallmarks of cancer: the next generation. Hanahan D, Weinberg RA, Cell 2011 144 5 646 674 10.1016/j.cell.2011.02.013 21376230
26. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG, Cancer Res 2004 64 6 1975 1986 10.1158/0008-5472.CAN-03-3972 15026333 (Pubitemid 38339443)
27. The epigenetic promise for prostate cancer diagnosis. Van Neste L, Herman JG, Otto G, Bigley JW, Epstein JI, Van Criekinge W, Prostate 2011 10 24 8472 8478 10.1002/pros.22459
28. A quantitative promoter methylation profile of prostate cancer. Jeránimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, Oliveira J, Teixeira MR, Lopes C, Sidransky D, Clin Cancer Res 2004 10 24 8472 8478 10.1158/1078-0432.CCR-04-0894 15623627 (Pubitemid 40053412)
29. Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis. Wu T, Giovannucci E, Welge J, Mallick P, Tang WY, Ho SM, Br J Cancer 2011 105 1 65 73 10.1038/bjc.2011.143 21654682
30. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB, Proc Natl Acad Sci USA 1996 93 18 9821 9826 10.1073/pnas.93.18.9821 8790415 (Pubitemid 26296693)
31. R: A language and environment for statistical computing R Foundation for Statistical Computing, Vienna 2009
32. ROCR: visualizing classifier performance in R. Sing T, Sander O, Beerenwinkel N, Lengauer T, Bioinformatics 2005 21 20 3940 3941 10.1093/bioinformatics/bti623 16096348 (Pubitemid 41535515)